Back by Popular Demand - KRAS G12C Mutation: An Emerging Biomarker for NSCLC Sponsored by Amgen®
Combating COVID-19 – Monoclonal Antibody Therapies to Optimize Patient Care: HHS/ASPR COVID-19 Therapeutics program
Myasthenia Gravis: How antibody testing helps you in the management of your patient
Give Us Your Feedback
The Rapid Bethesda Assay Is Equivalent to the Standard Bethesda Assay for Detection of Factor IX Inhibitors in Patients With Severe Haemophilia B
Prevalence of Suspected Direct Oral Anticoagulant Interference on Thrombophilia Testing at a US National Reference Laboratory.